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Abstract
Hyperbilirubinemia is a frequent condition affecting newborns during the first two weeks of life and when it lasts
more than 14 days it is defined as prolonged jaundice. This condition requires differential diagnosis between the
usually benign unconjugated hyperbilirubinemia and the pathological conjugated hyperbilirubinemia, that is mainly
due to neonatal cholestasis. It is important that the diagnosis of neonatal cholestasis be well-timed to optimize its
management, prevent worsening of the patient’s outcome, and to avoid premature, painful, expensive, and useless
tests. Unfortunately, this does not always occur and, therefore, the Task Force on Hyperbilirubinemia of the Italian
Society of Neonatology presents these shared Italian guidelines for the management and treatment of neonatal
cholestasis whose overall aim is to provide a useful tool for its assessment for neonatologists and family pediatricians.
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Background
Hyperbilirubinemia is a very common condition that can
occur in 2.4 to 15 % of newborns during the first two
weeks of life [1]. It is commonly due to an increase in
unconjugated bilirubin and resolves spontaneously.
Prolonged jaundice is defined as jaundice lasting more
than 14 days or recurring after the second week of
life [2, 3]. This condition requires careful evaluation
to differentiate unconjugated hyperbilirubinemia, that
is usually benign [4], from infrequent conjugated
hyperbilirubinemia, that is always pathological [3],
and is mainly due to neonatal cholestasis [3–5]. Many
pathologies can cause neonatal cholestasis and require
medical or surgical treatment. However, even when
specific treatment is not available or curative, infants
who have cholestasis may benefit from early medical
management and optimization of nutrition to prevent
complications. Therefore, it is important that the
diagnosis of neonatal cholestasis be well-timed, both
to prevent the worsening of the patient’s outcome
due to a delayed diagnosis [6], and to avoid carrying
out premature, painful, expensive, and useless tests.
Unfortunately, this does not always occur in practice
for several reasons, such as the early hospital discharge of
newborns without adequate follow-up of bilirubin serum
level, the misleading appearance of pigmented stool, and
misdiagnosis of breastfed–associated jaundice. In fact, all
these conditions are frequently cited as reasons for late
referral of infants for evaluation of cholestasis [7–9].
Focus of guidelines
These recommendations follow the recent publication
of the Italian guidelines for the management of
hyperbilirubinemia in infants ≥ 35 weeks’ gestational
age [10] and represent their completion. Their overall
aim is to provide a useful tool for neonatologists and
family pediatricians for the management of newborns
with cholestasis and to promote the prompt assessment of
infants with prolonged jaundice.
Methods of statement development
Literature searches were last updated in June 2015.
The hierarchy of evidence from the Center for
Evidence-Based-Medicine was applied (see Table 1) [11].
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Definition and incidence
Neonatal cholestasis results from impaired bile forma-
tion by hepatocytes or from the obstruction of bile flow
through the intra- or extrahepatic biliary tree leading to
the accumulation of biliary substances (bilirubin, bile
acids and cholesterol) in the liver, blood and extrahepatic
tissues [3, 4]. Although the laboratory methods used
need to be taken into account, neonatal cholestasis can
be defined as conjugated hyperbilirubinemia that occurs
when conjugated bilirubin is higher than 1 mg/dl, if the
total serum bilirubin is ≤5 mg/dl, or >20 % of total
serum bilirubin when it is >5 mg/dl [3–5].
The incidence of neonatal cholestasis is approximately
1 in 2,500 live births. The largest diagnostic groups are
biliary atresia, that comprises approximately one-third of
cases; α1-antitrypsin deficiency, that is the cause in 5-
15 %; inherited forms of cholestasis which occur in 10 %
to 20 % of cases; inborn errors of metabolism and con-
genital infections (including the TORCH infections), that
cause respectively 20 % and 5 % of cases; and parenteral
nutrition–associated cholestasis that is the commonest
cause in preterm infants [3, 5] (Table 2).
Clinical presentation
The clinical presentation of neonatal cholestasis may
vary in relation to its etiology. Nevertheless, the most
common findings in an infant who has cholestasis are
prolonged jaundice, acholic stools, dark yellow urine,
and hepatomegaly. Jaundice may decrease over the first
weeks of life as the indirect bilirubin decreases, thus
giving a false impression that the jaundice is resolving.
The presence of acholic stools is suggestive, but not
diagnostic of extrahepatic biliary obstruction, since this
can also be present in severe intrahepatic cholestasis.
On the other hand, the presence of pigmented stools
suggests patency of the extrahepatic biliary tree and
generally makes biliary atresia unlikely. However, in the
early course of biliary atresia, stools may appear nor-
mally or intermittently pigmented and, therefore, it is
important that stool color be serially assessed. Dark
urine is common as a non-specific indicator of conju-
gated hyperbilirubinemia, but is not pathognomonic.
Some infants show coagulopathy secondary to vitamin
K malabsorption and deficiency, and present with bleed-
ing (i.e.: gastrointestinal blood loss, bleeding from the
umbilical stump, intracranial hemorrhage). Coagulopa-
thy may also be caused by liver failure, indicating either
a severe metabolic hepatic disorders (as in respiratory
chain deficiency disorders) or cirrhosis and severe liver
disease (as in neonatal hemochromatosis). Splenomegaly
can be observed in about half of cases, particularly in in-
fants who have infections, cirrhosis and portal hyperten-
sion, storage diseases, and hemolytic disorder, but the
spleen is usually of normal size in the initial course of
extrahepatic biliary obstruction. Congenital infections
are associated with microcephaly, low birth weight,
intra-uterine growth restriction, chorioretinitis, and
thrombocytopenia. Dysmorphic facial features can
suggest syndromic and chromosomal disorders.
In an acutely ill infant sepsis, shock, heart failure, hypo-
pituitarism, and metabolic disorders such as galactosemia
or tyrosinemia should be evaluated promptly. Neuro-
logical abnormalities including irritability, lethargy, poor
feeding, hypotonia, or seizures can suggest sepsis.
Ocular manifestations can be found in Alagille syndrome,
optic nerve hypoplasia in panhypopituitarism, chorioretini-
tis in congenital infections, cataract in intra-uterine infec-
tions or galactosaemia, and ocular coloboma in Cat Eye
syndrome. Cardiac evaluation can reveal peripheral pul-
monary stenosis or other cardiac anomalies in Alagille syn-
drome, dextrocardia in biliary atresia, or patent ductus
arteriosus or septum defects in congenital infections. A
palpable mass in the right upper quadrant may indicate a
choledochal cyst.
The infant’s family history may provide important
information, such as consanguinity, while the obstetric
history may reveal maternal infection (i.e.: TORCH
infection, hepatitis B) or cholestasis of pregnancy
(which may be associated with progressive familial
intra-hepatic cholestasis).
Table 1 The hierarchy of evidence from the center for evidence-based-medicine
Level Definition
1a Systematic review (with homogeneity) of randomized clinical trials (RCTs)
1b Individual RCT (with narrow confidence interval)
2a Systematic review (with homogeneity) of cohort studies
2b Individual cohort study
3a Systematic review (with homogeneity) of case–control studies
3b Individual case–control study
4 Case-series (and poor quality cohort and case–control studies)
5 Expert opinion without explicit critical appraisal, or based on physiology, bench research or “first principles”
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Table 2 Differential diagnosis of neonatal cholestasis
Infections Inherited and metabolic disorders
Viral: Cytomegalovirus α1-antitrypsin deficiency
Rubella Galactosemia
Reovirus3 Glycogen storage disorder type IV
Adenovirus Fructosemia
Echovirus Cystic fibrosis
Coxsackie virus Hemochromatosis
Human herpes virus 6 Tyrosinemia
Varicella zoster Arginase deficiency
Herpes simplex Zellweger’s syndrome
Parvovirus Dubin-Johnson syndrome
Hepatitis B and C Rotor syndrome
Human immuno-deficiency virus Hereditary fructosemia
Bacterial: sepsis Niemann Pick disease, type C
Urinary tract infection Gaucher’s disease
Syphilis Wolman’s disease
Listeriosis Bile acid synthetic disorders
Tuberculosis Progressive familial intrahepatic cholestasis
Parasitic: Toxoplasmosis North American Indian familial cholestasis
Malaria Aagenaes syndrome
X-linked adreno-leukodystrophy
Chromosomal disorders Vascular disorders
Turner’s syndrome Budd-Chiari syndrome
Trisomy 18 Neonatal asphyxia
Trisomy 21 Multiple haemangiomata
Trisomy 13 Congestive heart failure
Cat-eye syndrome
Donahue’s syndrome (Leprechauns)
Bile duct anomalies Neoplastic disorders
Biliary atresia Neonatal leukemia
Choledochal cyst Histiocytosis X
Alagille syndrome Neuroblastoma
Non-syndromic bile duct paucity Hepatoblastoma
Inspissated bile syndrome Erythrophagocytic lymphohistiocytosis
Caroli syndrome
Choledocholithiasis
Gall-stones
Neonatal sclerosing cholangitis
Spontaneous common bile duct perforation
Toxicity Miscellaneous
Parenteral nutrition Neonatal lupus erythematosus
Fetal alcohol syndrome ’Le foie vide’ (infantile hepatic non-regenerative disorder)
Drugs Indian childhood cirrosi
ARC syndrome (Arthrogryposis, renal tubular dysfunction and cholestasis)
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Diagnosis
The most important initial investigation is the measure-
ment of fractionated serum bilirubin levels. As aforemen-
tioned, infants who have cholestasis will have >1 mg/dL
conjugated bilirubin when the total bilirubin is <5 mg/
dL or >20 % of the total bilirubin level if total bilirubin
is >5 mg/dL. Recently, it has been reported that in the
first 4 days of life, the cutoff for elevated conjugated
bilirubin may be >0.8 mg/dL and from 8 % to 10 % of
the total bilirubin [12]. It has also been suggested that
in the first 14 days after birth, the cutoff for elevated
conjugated bilirubin may be >0.5 mg/dL, and >2 mg/dL
for conjugated bilirubin [13].
Other biochemical markers can be increased in infants
with cholestasis, but they are neither diagnostic nor prog-
nostic: a serum transaminase (ALT, AST) increase indi-
cates an unspecific hepatocellular injury; elevated levels of
alkaline phosphatase can be found in biliary obstruction
but also in the course of bone and kidney diseases.
γ-Glutamyl transpeptidase (GGT) is an enzyme in
the biliary epithelium whose increase is strongly
associated with cholestatic disorders such as biliary
atresia, α1-antitrypsin deficiency, Alagille syndrome
and idiopathic neonatal hepatitis.
Many further biochemical measurements are useful in
identifying the etiology of cholestasis and must be
decided on the basis of different clinical situations
(i.e.: tests for metabolic inherited disorders, bacterial
blood culture or serologies, etc.).
Chest X-ray
This may be useful for assessing the presence of cardio-
vascular anomalies, which may be associated with biliary
atresia, and detecting skeletal abnormalities characteris-
tic of Alagille syndrome.
Ultrasonography
Abdominal ultrasound is an important tool in the diag-
nostic work-up of neonatal cholestasis and is the most
useful initial imaging study in the evaluation of neonatal
cholestasis [14]. It can assess the size and appearance of
the liver and gallbladder–including visualization of gall-
stones and biliary sludging. An ultrasound examination
can establish the diagnosis of choledochal cyst or dem-
onstrate a small or absent gallbladder that may suggest
(but is not diagnostic) biliary atresia. On the other hand,
the presence of a normal gallbladder does not exclude
biliary atresia. The finding of the triangular cord sign, an
echogenic area at the porta hepatis due to a fibrous tissue
cone, is specific for biliary atresia but is not diagnos-
tic [15, 16]. Common bile duct dilation is not seen in
biliary atresia and suggests a distal obstruction or a
fruste form of choledochal cyst.
Heart ultrasound should be performed when cardiac
anomalies are suspected (i.e.: in case of murmur). In
fact, up to 24 % of patients with Alagille syndrome and
a subset of biliary atresia patients have structural heart
disease [5].
Radionuclide imaging
Hepatobiliary scintigraphy is carried out using
Technetium-99 m-labeled immunodiacetic acid (IDA)
derivatives (Tc-99 IDA). The best resolution is achieved
if the patient is administered a pretreatment with pheno-
barbitone (5 mg/kg/d) for at least 3 days previously.. Ser-
ial images are taken for up to 24 h or until gut activity is
visualized. In a healthy infant, the injected radioisotope
is taken up by the hepatocytes, secreted into the biliary
system, and then excreted into the small intestine within
24 hours. Slow uptake of the injected radioisotope or
nonvisualization of the liver with persistence of the car-
diac pool suggests hepatocellular dysfunction, whereas
nonvisualization of the radioisotope in the small intes-
tine from 4 to 24 hours suggests either bile duct
obstruction or the severe inability of the hepatocyte to
secrete. The sensitivity of scintigraphy for biliary atresia
is relatively high (83 %–100 %); however, its specificity is
low (33 %–80 %) [17, 18]. A recent meta-analysis of 81
studies has shown a pooled sensitivity and specificity of
98.7 % and 70.4 %, respectively [19]. However, when an
acholic stool has been seen by an experienced observer
scintigraphy adds little information. In fact, since hepa-
tobiliary scintigraphy is expensive, time consuming and
poorly specific, many centers do not routinely use this
test in the evaluation of cholestatic infants because it
may delay the diagnostic evaluation without providing
definitive diagnostic information [15]. However, others
think that it still has a role where the liver biopsy is am-
biguous, and in the evaluation of preterm infants [5].
Recently it has been suggested that singlephoton emis-
sion computer tomography (SPECT) can improve the
specificity (81.1 %) of hepatobiliary scintigraphy allowing
better bowel visualization compared to planar images
[19]. However, only two studies have evaluated the
SPECT method and further studies are needed [20, 21].
Moreover, also the sampling of gastric and duodenal
fluids and measurement of their activities seems to
increase the accuracy of hepatobiliary scintigraphy. In
particular, gastrointestinal and duodenal fluid sampling
increases the specificity to 73.2 and 77.1 %, respectively.
Magnetic resonance cholangiography (MRC)
Magnetic resonance cholangiography (MRC) can be used
to assess the biliary tract. Non- visualization of the com-
mon bile duct and the presence of a small gallbladder have
been noted in biliary atresia. However, insufficient data
are available to recommend routinely this modality [22].
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Endoscopic retrograde cholangiography (ERC)
This method can be useful in the evaluation of infants
with biliary obstruction and, in experienced hands,
might be a useful tool in the evaluation of certain
individual cases. However, the need for high technical
expertise and general anesthesia for the study limits
its feasibility in some neonates. As a result ERC is of
limited usefulness for the evaluation of neonatal cho-
lestasis in most centers [15].
Liver biopsy
Liver biopsy is the single most definitive investigation in
the evaluation of neonatal cholestasis. In several single-
center studies, a diagnosis of biliary atresia was correctly
suggested by liver biopsy histological findings in 90 to
95 % of cases [23]. The diagnostic histologic appearances
of biliary atresia include bile duct proliferation, bile plugs
in the portal tract bile duct, portal tract edema and fibro-
sis. In addition to conventional histology, a wide range of
complementary techniques are used, when appropriate, to
improve diagnostic yield and can provide the diagnosis of
other specific conditions, such as α1-antitrypsin defi-
ciency, some metabolic liver diseases, Alagille syndrome,
neonatal sclerosing cholangitis, and viral infection (cyto-
megalovirus or herpes simplex).
Management of cholestasis
The first objective in the management of infants with cho-
lestasis is the recognition of diseases amenable to specific
medical therapy (i.e.: congenital toxoplasmosis, urinary
tract infection, galactosemia, tyrosinemia, hypothyroidism)
or early surgical intervention (biliary atresia, choledochal
cyst). In the remaining pathologies the medical manage-
ment of cholestasis is aimed mostly at treating the compli-
cations of chronic cholestasis, such as fat malabsorption
and fat-soluble vitamin deficiencies, pruritus, hypercholes-
terolemia, cirrhosis, portal hypertension and liver failure,
but cannot change the course of the disease.
Ursodeoxycholic acid (UDCA) has been found to have
beneficial effects on many forms of cholestasis, and is
generally used as first-line therapy for pruritus due to
cholestasis, parenteral nutrition-induced cholestasis, bil-
iary atresia after surgical treatment, and α1-antitrypsin
deficiency (evidence level 2b). Its mode of action is not
completely understood but appears to have two compo-
nents: (a) substitution in the bile acid pool for more hep-
atotoxic hydrophilic bile acids, and (b) stimulation of
bile flow. The dosage is 20–30 mg/kg/d in three divided
doses [24]. The only common side-effect is diarrhea
which usually responds to dose reduction. UDCA can be
discontinued when cholestasis has resolved.
Rifampicin inhibits bile acid uptake by hepatocytes and
induces hepatic microsomal enzymes. The recommended
dosage is 10 mg/kg/d. It is indicated in the management
of pruritus, but liver function should be monitored due to
potential hepatotoxicity (evidence level 4) [2, 4].
Cholestyramine may be useful in resistant pruritus and
severe hypercholesterolemia associated with cholestasis
(evidence level 4) [2, 4]. It acts by binding intestinal bile
acids and cholesterol, thus preventing reabsorption and
promoting bile acid synthesis from cholesterol. However,
cholestyramine may have side effects such as metabolic
acidosis, steatorrhea, and constipation. Doses of 250 mg/
kg/d are generally used.
Phenobarbital stimulates bile acid independent flow,
enhances bile acid synthesis, induces hepatic microsomal
enzymes and, hence, lowers the circulating bile acid levels,
but sedation and behavioral side effects limit its use. The
dosage is generally 3–10 mg/kg/d (evidence level 4) [2, 4].
Nutritional management of cholestatic infants
Infants with cholestasis often present steatorrhea and
increased energy expenditure. Therefore, caloric intake
should be approximately 125 % of the recommended diet-
ary allowance based on ideal body weight [3, 4]. Medium
chain triglycerides (MCT) are more readily absorbed than
long chain fatty acids and are a better source of fat
calories. In fact, MCTs are relatively water soluble, do
not require solubilization by bile acid micelles and
can be directly absorbed into the portal circulation
(evidence level 5).
The intestinal absorption of fat-soluble vitamins (A, D,
E and K) requires the presence of bile acids. Doses of at
least two to four times the recommended daily allow-
ance are given. Vitamin supplementation should con-
tinue at least three months after resolution of jaundice
as there is a delay before normal bile flow is established
(evidence level 5) (Table 3).
Neonatal phototherapy in cholestasis
Bronze baby syndrome is the dark gray-brown pigmenta-
tion of skin, mucous membrane and urine following photo-
therapy that occurs in some infants with cholestasis caused
by a poorly understood accumulation of the bilirubin
photoisomer, and/or porphyrins, and other metabolites,
and/or biliverdin [25]. This syndrome generally recovers
spontaneously and cholestasis does not contraindicate
phototherapy. The American Academy of Pediatrics sug-
gests that the direct (conjugated) serum bilirubin should
not be subtracted from the total serum bilirubin concentra-
tion in making decisions about exchange transfusions (evi-
dence level 5) [26]. Moreover, it suggests that in infants
who develop the bronze baby syndrome, exchange transfu-
sion should be considered when the total serum bilirubin
is in the intensive phototherapy range and phototherapy
does not promptly lower the total serum bilirubin (evi-
dence level 5) [26]. In fact, it has been reported that bronze
baby syndrome may be an additional risk of developing
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kernicterus (evidence level 4) [27]. However, the paucity of
data do not permit firm recommendations on this topic.
Specific diseases
Biliary Atresia
Biliary atresia is an idiopathic fibrosing cholangiopathy of
unknown etiology that leads to complete obstruction of
the extrahepatic bile duct during the first few months after
birth, progressive biliary cirrhosis, and eventual death if
left untreated. It occurs in 1 in 6,000 to 18,000 live births
and accounts for approximately one-third of the cases of
neonatal cholestasis [28]. It is the most important differ-
ential diagnosis in neonatal cholestasis because it should
be recognized and treated before the infant reaches the
60 days of age.
There are two clinical forms of biliary atresia: 80 % of
infants have isolated atresia without other congenital mal-
formations and are labeled as having the perinatal or so-
called acquired form; they show normal early growth, and
develop or have persisting jaundice and acholic stools at
approximately 3 to 6 weeks of age [5]. The remaining
20 % of infants who have biliary atresia have congenital
malformations, including biliary atresia splenic malforma-
tion syndrome or other isolated major congenital malfor-
mations (splenic and hepatic vascular anomalies, situs
inversus, congenital heart disease, etc.), and are labeled as
having the so-called fetal/embryonic form. These infants
may appear jaundiced at birth and remain so [4].
Children with biliary atresia are usually born after a nor-
mal pregnancy, show normal early growth, generally have
prolonged jaundice, and develop acholic stools at approxi-
mately 3 to 6 weeks of age [5]. Then they develop failure
to thrive, pruritus and coagulopathy, while physical exam-
ination indicates hepatomegaly and splenomegaly. Ascites
and other features of cirrhosis may be seen late in the
disease process [5].
Biochemical findings, abdominal ultrasound, and hepa-
tobiliary scintigraphy can be suggestive (see above) but are
not diagnostic. Liver biopsy can provide the diagnosis in
about 94 to 97 % of patients. The classic pathologic find-
ing is the presence of bile duct proliferation and bile plugs
with expansion of portal tracts. These findings, com-
bined with polymorphonuclear exudate and cholestasis,
are highly suggestive. However, liver biopsy can be am-
biguous in up to 10 % of cases, particularly when done
early in the disease process (less than 6 weeks age), and
in these cases it should be repeated [15].
α1-Antitrypsin deficiency has similar presentation as
biliary atresia and should be ruled out before laparotomy
[4], also because this condition can be worsened by por-
toenterostomy [29].
The standard treatment of biliary atresia is the Kasai
hepatic portoenterostomy with intraoperative cholangio-
gram to confirm the site of the obstruction before surgery.
The rate of success in re-establishing bile flow is dependent
on the age of the infant when the hepatic portoenterost-
omy is performed as well as on the experience of the sur-
geon [30]. There is up to an 80 % success rate if the
surgery takes place at less than 30 to 45 days of age; how-
ever, fewer than 20 % of patients who undergo hepatic por-
toenterostomy at older than 90 days achieve bile drainage
[31–33]. For these reasons a universal infant stool color
card screening program has been developed in some
countries, such as Taiwan [34] and Japan [35], because
it allows early diagnosis and better prognosis for pa-
tients with biliary atresia and, moreover, has been found
cost-effective [36].
The success of surgery is shown by the excretion of
bile and improvement of jaundice. The most significant
predictive factor of long-term prognosis is resolution of
jaundice. Patients who remain jaundiced usually die or
have liver transplantation by 8 years age. Jaundice-free
patients have a 10-year survival of almost 90 %. How-
ever, the majority of patients with biliary atresia have
progressive disease, with at least 80 % requiring liver
transplantation by age 20 years [37]. Of those who sur-
vive into the third decade after birth without transplant,
almost all have portal hypertension or other complica-
tions of cirrhosis.
Idiopathic neonatal hepatitis
Idiopathic neonatal hepatitis accounts for 25–30 % of
cases of neonatal cholestasis. There is no specific etiology,
and it represents an exclusion diagnosis confirmed by
specific histologic findings from liver biopsy of lobular
disarray, focal hepatic necrosis and giant cell transform-
ation with evidence of extramedullary hematopoiesis and
relatively normal portal tracts [2, 4].
These patients are more frequently preterm infants
and can be affected by intrauterine growth retardation.
Table 3 Fat-soluble vitamin supplementation in the cholestatic infant
Vitamin Preparation Dosage Adverse effects
Vitamin A Aquasol A 5000-25000 U/day per os Hepatotoxicity, Hypercalcemia,
Vitamin D Cholecalciferol 800-5000 U/day PO per os Hypercalcemia, Nephrocalcinosis
Vitamin E D-α-tocopheryl polyethylene glycol 1,000 succinate 15-25 U/kg/day PO per os Potentiation of vitamin K deficiency coagulopathy
Vitamin K Phytomenadione 2.5–5 mg twice a week to
every day per os
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The development of cholestasis generally occurs some
weeks after birth and may be associated with hepato-
megaly, a mild increase in transaminases, and normal or
low GGT; acholic stools are uncommon and are adverse
prognostic features [2, 4].
Management is usually supportive with nutritional sup-
port, vitamin supplementation and treatment of complica-
tions of cholestasis. Prognosis is good with >90 % clinical
and biochemical recovery by 1 year of age, with little risk
for chronic liver disease in familial cases. There is an
empirical 1 % recurrence in subsequent siblings [2, 4].
Cholestasis in preterm infants
Cholestasis is common in very preterm infants and its
etiology is multifactorial [38]. The immaturity of biliary
excretion can be exacerbated by further cholestatic
insults such as perinatal hypoxia, poor enteral feedings,
parenteral nutrition, drug toxicity, and sepsis. It has
been reported that 18 % to 67 % of infants who receive
prolonged courses of parental nutrition (longer than
14 days) develop liver injury and cholestasis [39].
Moreover, the occurrence of cholestasis associated
with parenteral nutrition is inversely correlated with
birth weight and directly with starvation and [40]
duration of parenteral nutrition [41].
The soybean-based lipid emulsion for parenteral nutri-
tion has been suggested to have a role in the pathogenesis
of cholestasis in preterm infants due to its phytosterol
content which is toxic and can lead to decreasing bile se-
cretion [42], and omega-6 fatty acids, that can act as pro-
inflammatory hepatic agents [43]. Cober et al. found that
the decrease of this intravenous fat emulsion in parenteral
nutrition from 3 to 1 g/kg/d two times per week can re-
duce total serum bilirubin without affecting growth (evi-
dence level 2b) [44]. However, Nehra et al. has recently
reported that the inclusion of soybean oil-based lipid
emulsion at 1 g/kg/d compared with 2–3 g/kg/d does not
reduce the incidence of cholestasis (evidence level 2b)
[45]. Fish oil-based lipid emulsions are composed of
omega-3 fatty acids and seem to be useful in treating neo-
natal cholestasis. Premkumar et al. demonstrated that fish
oil-based lipid emulsion monotherapy is effective in
promoting recovery from cholestasis in preterm infants
(evidence level 2b) [46]. Moreover, fish oil-based lipid
emulsion (i.e. Omegaven®) has been provided to hun-
dreds of infants with cholestasis and available data sug-
gest that from 80 to 90 % of them recover with a
decrease in their conjugated bilirubin of up to <0.5 mg/
dL. This high response rate explains the difficulty in per-
forming randomized controlled studies to compare the ef-
fect of soybean-based and fish oil-based lipid emulsions
on liver function (evidence level 2b) [43, 46, 47].
A novel lipid emulsion containing a mixture of soy-
bean oil, medium-chain triglycerides, olive oil, and fish
oil (SMOFlipid®) with reduced omega-6 fatty acids, in-
creased omega-3 fatty acids, and enriched in vitamin E
was found to decrease the gamma-glutamyl transferase
(GGT) serum level [48], oxidative stress [49], and retin-
opathy of prematurity [50] in preterm infants compared
with a soybean oil-based emulsion (evidence level 1b).
Another observational study reported that the use of
SMOFlipid® in parenteral nutrition is also associated
with the decrease in bronchopulmonary dysplasia and a
trend toward a lower incidence of cholestasis in prema-
ture infants [51] (evidence level 2b).
Because fish oil-based lipid emulsions are so beneficial
for the treatment of parenteral nutrition-associated chole-
stasis, it has been suggested that they may have potential
in preventing it, but this has not been confirmed [51, 52]
(evidence level 2b) and further studies are needed to eluci-
date this question in preterm infants. Nevertheless, con-
sidering the lack of adverse effects of these emulsions in
supplemented infants and that both Omegaven® and
SMOFlipid® have been found to prevent cholestasis and
hepatic steatosis in the preterm animal model [53], we
believe that fish oil-based lipid emulsions should be
preferred to soybean-based lipid emulsion for parenteral
nutrition in preterm infants from the beginning.
Taurine supplementation seems to offer a significant
degree of protection against parenteral nutrition-
associated cholestasis, particularly in patients with nec-
rotizing enterocolitis or severe prematurity, but this
effect has not yet been definitively demonstrated (evi-
dence level 2b) [54].
The management of cholestasis in preterm infants
should include the discontinuation of parenteral nutrition
as soon as possible and the promotion of enteral feeding
(also trophic feeding) that enhances bile flow, gallbladder
contraction, and intestinal motility. Treatment with UDCA
(see the section Management of cholestasis) may be given
although there is no evidence of its efficacy in this specific
pathology. High (12.5 mg/kg/dose every 6 hours for
14 days) [55, 56] and intermediate-dose (5 mg/kg/dose
every 6 hours for 14 days) oral erythromycin has been
found to decrease the incidence of parenteral nutrition-
associated cholestasis in preterm infants who fail to es-
tablish adequate enteral nutrition due to its prokinetic
action (evidence level 1b). A meta-analysis of these two
randomized controlled studies confirmed a significant
beneficial effect of erythromycin in preventing paren-
teral nutrition-associated cholestasis [57].
Cholecystokinin has been suggested for preventing
cholelithiasis or liver disease in patients receiving par-
enteral nutrition by stimulating the gallbladder, but it
was not found to be effective in preventing parenteral
nutrition-associated cholestasis (evidence level 2b) [58].
The prognosis of preterm infants with cholestasis is
generally excellent and discontinuation of parenteral
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nutrition is followed by its progressive disappearance
and normalization of its biochemical markers.
The risk of biliary atresia is uncommon in preterm in-
fants so a modified schedule of investigation is appropri-
ate (Fig. 1). Hepatobiliary scintigraphy and liver biopsy
should be delayed until the infant’s corrected gestational
age is more than one term and his/her weight is more
than 2 kg unless there is biliary dilation. Liver biopsy is
indicated in the presence of acholic stools, cholestasis
which persists beyond a corrected age of 2–3 months,
and in patients who have a nonexcreting hepatobiliary
scan [2, 4].
α1-Antitrypsin deficiency
This autosomal recessive disorder is the most common
inherited cause of neonatal cholestasis. α1-Antitrypsin is
the most abundant circulating proteinase inhibitor and
acts to protect tissues by inhibiting destructive proteases.
In patients with α1-antitrypsin deficiency this protein fails
to be secreted normally by the hepatocyte, leading to a de-
crease in its activity in the blood and lungs, and excessive
retention in hepatocytes. The mechanism of liver disease
is unclear but is related to the accumulation of the mutant
α1-antitrypsin which can polymerize in vivo [59], while its
deficiency leads to a failure to neutralize neutrophil lung
elastase and causes the early development of emphysema.
More than 75 different variants of α1-antitrypsin mutants
have been found, M being the normal variant and Z the
most common deficient variant [60]. 95 % of the Northern
European population are homozygous for the M allele and
2–3 % carry the Z mutation.1:2000–3000 are homozygous
for ZZ deficiency which is associated with neonatal liver
disease and adult emphysema [61]. However, only 15 % of
ZZ neonates develop clinical disease within the first
20 years and the development of disease in individual
patients is probably a complex balance between environ-
mental factors which increase α1-antitrypsin production,
genetic factors which regulate degradation of mutant α1-
antitrypsin, and physical factors (such as fever) which pro-
mote polymerization of the mutant α1-antitrypsin [61].
Forty to 50 % of infants who have the ZZ phenotype may
have asymptomatic abnormal liver biochemical tests in the
first year after birth, and 10 % to 15 % develop neonatal
cholestasis. However, fewer than 25 % of those presenting
with cholestasis progress to end-stage liver disease during
childhood [62], and liver transplantation has resulted in
good survival rates of 90 % at 1 year and 80 % at 5 years
[63]. Clinical features are similar to biliary atresia but these
patients are more likely to have intrauterine growth retard-
ation, and vitamin K-responsive coagulopathy. Diagnosis is
made by documenting low plasma levels of α1-antitrypsin
and demonstrating the α1-antitrypsin phenotype. More-
over, α1-antitrypsin is an acute phase protein and its value
could be normal during inflammation processes, and,
therefore, the deficient α1-antitrypsin variants have to be
identified by protease inhibitor typing.
There is no specific treatment for α1-antitrypsin defi-
ciency. Management is mostly supportive with nutri-
tional supplementation to maintain adequate growth.
Progressive familial intrahepatic cholestasis (PFIC)
These are a group of at least three autosomal recessive
hereditary disorders characterized by mutations in hepa-
tocellular bile acid transport-system genes leading to im-
paired bile formation that show progressive intrahepatic
cholestasis whose diagnosis must be confirmed by liver
histology at biopsy.
In PFIC type 1 and PFIC type 2 patients typically have
low or normal GGT levels, low cholesterol levels, and de-
velop early cholestasis. PFIC-1 is caused by mutation in
the FIC 1 gene and is the original Byler disease described
in the descendants of an Amish American family. It
appears to be an allelic disorder with benign recurrent
intrahepatic cholestasis. The function of the FIC1 protein
that is expressed in hepatocyte canalicular membranes is
unknown [64], but patients who have PFIC-1 may also
have severe diarrhea, pancreatitis, and hearing loss. Surgi-
cal methods such as ileal exclusion and partial external
biliary diversion may be effective [65]. Cirrhosis develops
by the end of the first decade and liver transplantation is
usually required during the second decade.
PFIC-2 is caused by a defect in the canalicular bile salt
excretory pump (BSEP). The clinical and biochemical
presentation is similar to PFIC-1, but without pancrea-
titis. Treatment is similar to PFIC-1, but the prognosis is
worse, with most patients requiring transplantation in
the first decade of life [66]. PFIC-3 is caused by a defect
in the canalicular phospholipid transporter MDR3. Clin-
ical presentation is similar to PFIC-1 but is delayed until
early adulthood. There may be a history of maternal
cholestasis in pregnancy. GGT is markedly elevated and
bile analysis shows a high bile acid to phospholipid ra-
tio. Pruritus is less severe than in the other forms of
PFIC and is often responsive to UDCA. Treatment is
similar to other types, prognosis is variable and difficult
to predict in individual cases [64].
Alagille syndrome
Alagille syndrome is an autosomal dominant multisys-
tem disorder characterized by a paucity of intralobular
bile ducts and occurring in approximately 1:70,000-
100,000 live births. Almost all patients (90 %) have a
mutation in the JAGGED 1 gene that encodes a ligand
in the Notch signaling pathway, while others have less
frequent NOTCH-2 receptor mutations. Patients with
Alagille syndrome have a combination of characteristics
including chronic cholestasis; a characteristic face with
triangular shape, broad forehead, deep-set eyes, small
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Fig. 1 Flow chart for the management of the neonatal cholestasis in term and preterm infants. Modified from ’ with permission
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pointed chin, and bulbous nose; skeletal anomalies includ-
ing butterfly vertebrae, curved phalanges, and short ulna;
cardiac anomalies, most commonly peripheral pulmonary
stenosis; ocular anomalies such as posterior embryotoxon
and optic nerve drusen. Other findings include renal ab-
normalities such as ectopic kidney; mental retardation and
developmental delay; growth retardation, short stature
and pancreatic insufficiency.
Infants usually present with neonatal cholestasis. It may
be difficult to differentiate from biliary atresia because in
some cases initial liver biopsy may show bile duct prolifera-
tion, and the characteristic facies may not be evident in the
neonatal period. Management is mostly supportive with
adequate nutritional intake and treatment of pruritus.
Supplementation of fat-soluble vitamins and pancre-
atic enzymes is needed. The Kasai procedure should
be avoided as it does not improve outcome and may
worsen it.
The outcome of Alagille syndrome is largely dependent
on the individual’s clinical manifestations, especially the
severity of the cardiac and renal lesions. For those present-
ing with cholestatic liver disease in infancy, 20 % to 50 %
will require liver transplantation or succumb to cardiac or
renal disease by the age of 20 years [67]. More than half of
children presenting with neonatal cholestasis progress to
cirrhosis and require liver transplantation by age 10.
Moreover, the occurrence of hepatocellular carcinoma has
been reported in patients with Alagille syndrome [68].
Recommendations
– Neonates with prolonged jaundice (>14 days) must be
assessed for cholestasis by measuring fractioned
serum bilirubin level, AST, ALT, alkaline phosphatase,
GGT, serum albumin, coagulation tests.
– Neonates with conjugated serum bilirubin >1 mg/dl,
if the total serum bilirubin is ≤5 mg/dl, or >20 % of
total serum bilirubin, when it is >5 mg/dl, are
diagnosed to have neonatal cholestasis.
– Neonates with cholestasis must be checked with
biochemical and instrumental tests, and possibly
liver biopsy to establish the differential diagnosis as
summarized in Fig. 1.
– Late diagnosis of biliary atresia must be avoided
because its surgical treatment is much more
successful when performed before 30 to 45 days
of life.
– The diagnostic approach must be delayed in preterm
infants because of the high occurrence of self-limiting
parenteral nutrition-associated cholestasis in these
patients.
– Fish oil-based lipid emulsions should be used instead
of soybean-based lipid emulsion for parenteral nutri-
tion in preterm infants.
– Oral treatment with erythromycin may be considered
in preterm infants who fail to establish adequate
enteral nutrition due to its prokinetic action for the
prevention of parenteral nutrition-associated
cholestasis.
– When specific treatments are available they must
be started and associated with UCDA treatment at
the dosage of 20–30 mg/kg/d in divided doses.
UDCA can be discontinued when the cholestasis
has resolved.
– Infants with cholestasis must be given a caloric
intake of approximately 125 % more than the
recommended dietary intake for healthy infants with
a preference for MCT as a lipid source. Adequate
supplementation with vitamins A, D, E, and K must
be guaranteed.
– Cholestasis is not a contraindication for
phototherapy. The conjugated serum bilirubin
should not be subtracted from the total serum
bilirubin concentration in making decisions about
exchange transfusions.
Conclusions
The development of national guidelines helps to
standardize the management of neonatal cholestasis
both in term and preterm infants. This pathology can
be unrecognized or misdiagnosed, leading to a sub-
optimal clinical assessment and to a worsening of the
patient’s outcome due to a delayed diagnosis. We are
confident that these guidelines will enhance the diffu-
sion of a systematic approach to the management of
neonatal cholestasis and contribute to limiting the tra-
gic underestimation and late referral of this pathology.
The development of a stool color card screening pro-
gram could be a useful tool for improving the prognosis
for patients with biliary atresia in the next future.
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